Want to join the conversation?
$ILMN said oncology shipments grew 9% adjusted for the large HiSeq X shipments seen in 1Q15. This growth rate is lower than what is typically seen from this market due to a large number of orders shipped in the prior year period. The company expects expanded adoption in 2016, fueled in part by the TruSight Tumor 170 launch later this year.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.